Courtesy of renalandurologynews.com
Obese hypogonadal men
who received long-term testosterone injections experience a gradual
decline in weight and waist circumference, according to study findings
presented at the 33rd Congress of the Societé Internationale d'Urologie.
This effect, researchers concluded, may be beneficial for cardio-metabolic and urological outcomes.
Abdulmaged Traish, MBA, PhD, professor of biochemistry and urology at
Boston University School of Medicine, led the prospective, Bayer-funded
registry study of 181 men who, at baseline, had a testosterone level
below 12.1 nmol/L and a body mass index (BMI) of at least 30 kg/m2.
Subjects' mean age was 59.1 years (range 33-69 years). Each received
one 1,000-mg testosterone undecanoate parenteral injection and, starting
six weeks later, received this same dose every 12 weeks for up to five
years.
All of the men had dyslipidemia, 97% had hypertension, 39% had
type 2 diabetes, 22% had coronary artery disease, and 19% had
experienced a previous myocardial infarction. One patient was diagnosed
with prostate cancer after 10 months of treatment.
The researchers tracked subjects' testosterone trough levels and
found that, starting at 12 months of treatment and going out to 60
months, the levels were significantly higher than baseline levels. At
the same time, subjects' body weights and waist circumferences fell
significantly. They lost an average of 18.83 kg from a baseline average
weight of 114 kg, and 9.87 cm from an average baseline waist
circumference of 111 cm. The men's mean BMI also declined significantly,
from 36.72 kg/m2 at baseline to 30.22 kg/m2 at the 60-month mark.
These changes took place gradually, with the men experiencing
significant year-to-year weight, waist circumference, and BMI losses
each year. Ninety-nine percent of the men lost at least 5 kg over the
five-year period, while 70% lost at least 15 kg and 40% lost at least 20
kg.
About 3%-5% of the men gained weight, averaging 1-2 kg. “Most of
these men have some inflammatory diseases, and the weight gain is
explained by the fact that their inflammation got better and they were
able to gain some weight,” Dr. Traish said.
Other changes the men experienced over the duration of the study included a:
· gradual and steady drop in average residual bladder volume, starting at 52 mL and falling to 20.5 mL by 57 months;
· gradual increase in average prostate volume, starting at 31
mL, rising to 34 mL at three years and falling again to 32 mL at 60
months;
· slight but statistically significant increase in average
PSA levels, starting at 1.8 ng/mL and rising to 1.95 ng/mL at the
five-year mark;
· steady drop in average International Prostate Symptom
Score, falling from 7.8 at baseline to 3.5 at three years and 2.9 at
five years;
· sharp fall in average C-reactive protein levels, from 4.0 mg/dL at baseline to 0.8 mg/dL at five years; and,
· gradual increase in average score on the International
Index of Erectile Function-Erectile Function subscale, starting at 21.1
at baseline and reaching 25.25 at the 60-month mark.
Long-term testosterone treatment also produced positive effects on
lipid profiles (reduction in total and LDL cholesterol, increased HDL
cholesterol, and reduction in triglycerides), and decreases in fasting
blood glucose, hemoglobin A1c, and inflammation. The study has been
accepted for publication in the International Journal of Clinical Practice.
No comments:
Post a Comment
All coments are moderated. Obscenities get you tossed out. Do not leave personal info incomments, but professional contact info is accepted.